Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI.

At the 15mg dose, participants showed a sustained average weight loss of 22.9% during the three-year treatment. Credit: SB ...

The DACH region encompasses Germany, Austria, and Switzerland. Credit: Tom Korcak via Shutterstock. Amid tightening EU ...

They say lightning rarely strikes twice but Kezar Life Sciences has suffered its second clinical blow in as many months.

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...

Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...